Circulating tumor DNA in early-stage breast cancer : personalized biomarkers for occult metastatic disease and risk of relapse?

Show full item record



Permalink

http://hdl.handle.net/10138/161935

Citation

af Hallstrom , T M , Puhka , M & Kallioniemi , O 2015 , ' Circulating tumor DNA in early-stage breast cancer : personalized biomarkers for occult metastatic disease and risk of relapse? ' , EMBO molecular medicine , vol. 7 , no. 8 , pp. 994-995 . https://doi.org/10.15252/emmm.201505332

Title: Circulating tumor DNA in early-stage breast cancer : personalized biomarkers for occult metastatic disease and risk of relapse?
Author: af Hallstrom, Taija M.; Puhka, Maija; Kallioniemi, Olli
Contributor: University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Institute for Molecular Medicine Finland
Date: 2015-08
Language: eng
Number of pages: 2
Belongs to series: EMBO molecular medicine
ISSN: 1757-4676
URI: http://hdl.handle.net/10138/161935
Abstract: The availability of blood-based markers topredict response of a solid tumor to treatment, estimate patient prognosis and diagnose relapse well before clinical symptoms arise, is a long-standing hope in clinical oncology. Ideally, assays designed to provide such information should be inexpensive (at least in the foreseeable future), simple, and, of course, predictive of the clinical evolution of the disease. While early research focused on circulating glycosylated tumor-derived protein biomarkers, the focus is now rapidly shifting to new opportunities, such as circulating tumor cells, extracellular vesicles, micro-RNAs and cancer-derived cell-free DNA a.k.a. circulating tumor-derived DNA (ctDNA).
Subject: 3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
994.full.pdf 137.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record